Brooks Laboratories Limited (BROOKS) - Net Assets
Based on the latest financial reports, Brooks Laboratories Limited (BROOKS) has net assets worth Rs1.16 Billion INR (≈ $12.51 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs1.40 Billion ≈ $15.13 Million USD) and total liabilities (Rs242.82 Million ≈ $2.63 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BROOKS tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs1.16 Billion |
| % of Total Assets | 82.65% |
| Annual Growth Rate | 25.03% |
| 5-Year Change | 23.95% |
| 10-Year Change | -19.62% |
| Growth Volatility | 93.21 |
Brooks Laboratories Limited - Net Assets Trend (2007–2025)
This chart illustrates how Brooks Laboratories Limited's net assets have evolved over time, based on quarterly financial data. See BROOKS defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Brooks Laboratories Limited (2007–2025)
The table below shows the annual net assets of Brooks Laboratories Limited from 2007 to 2025. For live valuation and market cap data, see BROOKS market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs981.04 Million ≈ $10.61 Million |
+49.58% |
| 2024-03-31 | Rs655.85 Million ≈ $7.09 Million |
-11.32% |
| 2023-03-31 | Rs739.53 Million ≈ $8.00 Million |
-44.94% |
| 2022-03-31 | Rs1.34 Billion ≈ $14.53 Million |
+69.71% |
| 2021-03-31 | Rs791.48 Million ≈ $8.56 Million |
-19.58% |
| 2020-03-31 | Rs984.16 Million ≈ $10.64 Million |
-6.40% |
| 2019-03-31 | Rs1.05 Billion ≈ $11.37 Million |
-8.14% |
| 2018-03-31 | Rs1.14 Billion ≈ $12.38 Million |
-7.69% |
| 2017-03-31 | Rs1.24 Billion ≈ $13.41 Million |
+1.60% |
| 2016-03-31 | Rs1.22 Billion ≈ $13.20 Million |
+9.54% |
| 2015-03-31 | Rs1.11 Billion ≈ $12.05 Million |
-0.78% |
| 2014-03-31 | Rs1.12 Billion ≈ $12.14 Million |
+6.53% |
| 2013-03-31 | Rs1.05 Billion ≈ $11.40 Million |
+15.50% |
| 2012-03-31 | Rs912.63 Million ≈ $9.87 Million |
+369.77% |
| 2011-03-31 | Rs194.27 Million ≈ $2.10 Million |
+42.41% |
| 2010-03-31 | Rs136.42 Million ≈ $1.48 Million |
+59.80% |
| 2009-03-31 | Rs85.37 Million ≈ $923.22K |
+73.83% |
| 2008-03-31 | Rs49.11 Million ≈ $531.11K |
+179.29% |
| 2007-03-31 | Rs17.58 Million ≈ $190.16K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Brooks Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 48651700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs294.57 Million | 30.03% |
| Other Comprehensive Income | Rs2.81 Million | 0.29% |
| Other Components | Rs1.17 Billion | 119.28% |
| Total Equity | Rs981.04 Million | 100.00% |
Brooks Laboratories Limited Competitors by Market Cap
The table below lists competitors of Brooks Laboratories Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TPC Plus Bhd
KLSE:7176
|
$21.67 Million |
|
B3 Consulting Group AB
ST:B3
|
$21.67 Million |
|
MDI Energia S.A.
WAR:MDI
|
$21.67 Million |
|
Matching Maximize Solution Public Company Limited
BK:MATCH
|
$21.68 Million |
|
PJX Resources Inc
V:PJX
|
$21.63 Million |
|
Elevation Oncology Inc
NASDAQ:ELEV
|
$21.63 Million |
|
Solarmax Technology Inc. Common Stock
NASDAQ:SMXT
|
$21.62 Million |
|
Shanyuan Co Ltd
TWO:4416
|
$21.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Brooks Laboratories Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 655,853,000 to 981,043,000, a change of 325,190,000 (49.6%).
- Net loss of 99,670,000 reduced equity.
- Share repurchases of 425,043,000 reduced equity.
- New share issuances of 425,043,000 increased equity.
- Other comprehensive income decreased equity by 183,000.
- Other factors increased equity by 425,043,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs-99.67 Million | -10.16% |
| Share Repurchases | Rs425.04 Million | -43.33% |
| Share Issuances | Rs425.04 Million | +43.33% |
| Other Comprehensive Income | Rs-183.00K | -0.02% |
| Other Changes | Rs425.04 Million | +43.33% |
| Total Change | Rs- | 49.58% |
Book Value vs Market Value Analysis
This analysis compares Brooks Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.10x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 44.86x to 2.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-03-31 | Rs1.52 | Rs68.00 | x |
| 2008-03-31 | Rs4.17 | Rs68.00 | x |
| 2009-03-31 | Rs27.55 | Rs68.00 | x |
| 2010-03-31 | Rs11.61 | Rs68.00 | x |
| 2011-03-31 | Rs16.49 | Rs68.00 | x |
| 2012-03-31 | Rs47.01 | Rs68.00 | x |
| 2013-03-31 | Rs54.30 | Rs68.00 | x |
| 2014-03-31 | Rs57.85 | Rs68.00 | x |
| 2015-03-31 | Rs57.40 | Rs68.00 | x |
| 2016-03-31 | Rs62.87 | Rs68.00 | x |
| 2017-03-31 | Rs63.88 | Rs68.00 | x |
| 2018-03-31 | Rs58.97 | Rs68.00 | x |
| 2019-03-31 | Rs52.31 | Rs68.00 | x |
| 2020-03-31 | Rs55.34 | Rs68.00 | x |
| 2021-03-31 | Rs31.73 | Rs68.00 | x |
| 2022-03-31 | Rs35.07 | Rs68.00 | x |
| 2023-03-31 | Rs29.65 | Rs68.00 | x |
| 2024-03-31 | Rs25.60 | Rs68.00 | x |
| 2025-03-31 | Rs32.40 | Rs68.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Brooks Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12.07%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 1.26x
- Recent ROE (-10.16%) is below the historical average (5.98%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 63.97% | 4.82% | 1.56x | 8.52x | Rs9.49 Million |
| 2008 | 65.71% | 11.46% | 1.11x | 5.17x | Rs27.36 Million |
| 2009 | 34.72% | 6.60% | 1.40x | 3.76x | Rs21.10 Million |
| 2010 | 37.91% | 11.48% | 1.21x | 2.73x | Rs38.08 Million |
| 2011 | 35.46% | 13.11% | 1.29x | 2.10x | Rs49.45 Million |
| 2012 | 9.68% | 15.76% | 0.53x | 1.16x | Rs-2.90 Million |
| 2013 | 6.78% | 8.92% | 0.61x | 1.25x | Rs-33.97 Million |
| 2014 | 6.45% | 8.49% | 0.61x | 1.25x | Rs-39.90 Million |
| 2015 | 8.50% | 11.11% | 0.63x | 1.21x | Rs-16.74 Million |
| 2016 | 8.71% | 13.29% | 0.52x | 1.25x | Rs-15.72 Million |
| 2017 | 1.58% | 3.40% | 0.35x | 1.32x | Rs-104.44 Million |
| 2018 | -12.07% | -24.79% | 0.32x | 1.51x | Rs-252.60 Million |
| 2019 | -14.08% | -26.90% | 0.33x | 1.60x | Rs-253.20 Million |
| 2020 | -24.77% | -35.26% | 0.44x | 1.60x | Rs-342.18 Million |
| 2021 | -24.48% | -25.14% | 0.48x | 2.05x | Rs-272.90 Million |
| 2022 | -22.07% | -21.18% | 0.47x | 2.24x | Rs-280.62 Million |
| 2023 | -28.26% | -33.45% | 0.57x | 1.48x | Rs-282.96 Million |
| 2024 | -29.87% | -24.65% | 0.88x | 1.38x | Rs-261.50 Million |
| 2025 | -10.16% | -12.07% | 0.67x | 1.26x | Rs-197.77 Million |
Industry Comparison
This section compares Brooks Laboratories Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $41,118,163,484
- Average return on equity (ROE) among peers: 13.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Brooks Laboratories Limited (BROOKS) | Rs1.16 Billion | 63.97% | 0.21x | $21.66 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $366.97 Million | 3.51% | 2.41x | $25.11 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.23 Billion | 12.93% | 2.27x | $365.36 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $2.31 Million | -8.08% | 0.08x | $645.54 Million |
| Abbott India Limited (ABBOTINDIA) | $2.31 Billion | 29.62% | 0.43x | $6.01 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $32.64 Billion | 21.83% | 0.24x | $4.15 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.23 Billion | 13.11% | 3.52x | $996.26 Million |
| Alkem Laboratories Limited (ALKEM) | $75.58 Billion | 20.97% | 0.52x | $6.95 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.09 Billion | 18.92% | 0.29x | $170.62 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $22.20 Billion | 18.58% | 0.77x | $1.59 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $268.52 Billion | 7.18% | 0.49x | $8.98 Billion |
About Brooks Laboratories Limited
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company's product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and d… Read more